NURR1 regulation by heterodimerization with RXR is one exception that appeared in a preclinical translational study in mouse PD models [123], using pharmacological approaches that regulate and improve its activity, either onset or impairment progression of the physio-pathological condition [18,69,70,71]. The gene discussed is NR4A2; the disease is Parkinson disease.